Form 4: Bausch & Lomb EVP and CFO Sam Eldessouky Reports Stock and Option Grants

Sam Eldessouky, EVP and CFO of Bausch & Lomb, reports the acquisition of restricted stock units and stock options.

Summary

• On February 26, 2025, Sam Eldessouky, the EVP and CFO of Bausch & Lomb Corp, was granted 59,459 restricted stock units (RSUs) and 141,630 stock options.
• The RSUs vest in equal installments over three years from the grant date.
• The stock options also vest in equal installments over three years from the grant date and expire ten years from the grant date.
• The exercise price for the stock options is $15.86.
• Following these transactions, Eldessouky directly owns 282,295 common shares and 141,630 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning management with shareholder interests. There are no indications of negative performance or concerns.

Positives

• The grant of RSUs and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Executive compensation packages including stock options and RSUs are common practice in publicly traded companies to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and medical device industries.
• Companies like Johnson & Johnson and Abbott Laboratories also utilize stock options and RSUs as part of their executive compensation plans.
• The vesting schedules and exercise prices are generally aligned with industry norms to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the grants positively as they incentivize management to improve company performance.
• Employees may see the grants as a sign of confidence in the company's future.

Key Dates